Abstract
As with many chronic illnesses, recurrent prostate cancer generally requires sustained treatment to prolong survival. However, initiating treatment immediately after recurrence may negatively impact quality of life without any survival gains. Therefore, we consider sustained strategies for initiating treatment based on specific characteristics of prostate-specific antigen (PSA), which can indicate disease progression. We define the protocol for a target trial comparing treatment strategies based on PSA doubling time, in which androgen deprivation therapy is initiated only after doubling time decreases below a certain threshold. Such a treatment strategy means the timing of treatment initiation (if ever) is not known at baseline, and the target trial protocol must explicitly specify the frequency of PSA monitoring until the threshold is met, as well as the duration of treatment. We describe these and other components of a target trial that need to be specified in order for such a trial to be emulated in observational data. We then use the parametric g-formula and inverse-probability weighted dynamic marginal structural models to emulate our target trial in a cohort of prostate cancer patients from clinics across the United States.
Similar content being viewed by others
References
Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.
Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766–79.
Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ (Online). 2009;338:395–9.
Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250–62.
Petito LC, García-Albéniz X, Logan RW, et al. Estimates of overall survival in patients with cancer receiving different treatment regimens. JAMA Netw Open. 2020;3:1–13.
Lodi S, Phillips A, Lundgren J, et al. Effect estimates in randomized trials and observational studies: comparing apples with apples. Am J Epidemiol. 2019;188:1569–77.
Artibani W, Porcaro AB, De Marco V, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100:251–62.
Higano CS. Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw. 2014;12:727–33.
Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content. Int J Biostat. 2010;6:44398–9.
Cain LE, Robins JM, Lanoy E, et al. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6:1–42.
Robins J. A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. J Chronic Dis. 1987;40(Suppl 2):139S-161S.
Young JG, Cain LE, Robins JM, et al. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci. 2011;3:119–43.
Garcia-Albeniz X, Chan JM, Paciorek A, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015;51:817–24.
Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17:727–37.
Loblaw A, Bassett J, D’Este C, et al. Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials. J Clin Oncol. 2018;36:5018–5018.
Klayton TL, Ruth K, Buyyounouski MK, et al. Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition. Pract Radiat Oncol. 2011;1:235–42.
Hernán MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377:1391–8.
Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA. J Am Med Assoc. 1999;281:1591–7.
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779–88.
Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology. 1996;48:773–7.
Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research Endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393–401.
Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941–9.
R Core Team. R 3.4.3. 2017.
McGrath S, Lin V, Zhang Z, et al. gfoRmula: An R package for estimating the effects of sustained treatment strategies via the parametric g-formula. Patterns. 2020;1: 100008.
NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. National Comprehensive Cancer Network; 2018.
Lonergan PE, Washington SL, Cowan, JE, et al. Androgen deprivation therapy and the risk of dementia after treatment for prostate cancer. J Urol. 2021; epub ahead of print.
Botrel TEA, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9.
Funding
The authors declare that no funds, grants, or other support directly supported the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
This study was approved by the Harvard Longwood Campus Insitutional Review Board (IRB13-2919).
Consent to participate
Informed consent was obtained from all CaPSURE participants.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Smith, L.H., García-Albéniz, X., Chan, J.M. et al. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula. Eur J Epidemiol 37, 1205–1213 (2022). https://doi.org/10.1007/s10654-022-00929-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-022-00929-7